Site Editor
Jeremy S. Abramson, MD, MMSc
Jeremy S. Abramson, MD, MMSc
Posted: Tuesday, January 21, 2025
Monotherapy with the ROR1-targeting antibody-drug conjugate zilovertamab vedotin demonstrated antitumor activity and a manageable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma, according to Ingrid Glimelius, MD, PhD, of Uppsala University, Sweden, and colleagues. These results from cohort A of the multicenter phase II waveLINE-006 trial were presented during the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 4405).
A total of 40 patients who received at least two prior systemic therapies (including a Bruton’s tyrosine kinase inhibitor) were treated with 2.5 mg/kg of zilovertamab vedotin intravenously every 3 weeks. The median time from the first dose to data cutoff was 11.9 months.
The objective response rate, including complete (13%) and partial (28%) responses, was 40%. More than half of the patients who had one or more postbaseline target lesions (n = 16 of 28; 57%) showed a reduction of at least 50% in their size. The median duration of response was 3.0 months. The median progression-free survival was 3.4 months, and the 6-month rate was 26%. These values were 9.0 months and 67%, respectively, for overall survival.
The majority of patients (90%) experienced a treatment-related adverse event; neutropenia (58%), peripheral neuropathy (43%), and diarrhea (28%) were among the most frequently reported. Treatment-related adverse events of grade 3 or 4 were observed in 80% of patients; the most common were neutropenia (50%) and peripheral neuropathy (18%). The median time to the onset of first peripheral neuropathy was 61 days. Grade 3 tumor-lysis syndrome was seen in one patient (3%). A total of 18% of patients discontinued treatment because of related adverse events. The investigators reported no treatment-related deaths.
“Further investigation is warranted to better understand the efficacy of zilovertamab vedotin for relapsed or refractory mantle cell lymphoma,” the investigators concluded.
Disclosure: For full disclosures of the study authors, visit ash.confex.com.
2024 ASH Annual Meeting & Exposition
JNCCN Spotlights
